Table 4 Overall survival analysis (N = 438 patients)*

 Gastrointestinal (n = 123) vs not

36.3 (4.5) vs 71.6 (6.5)

0.002

–

–

–

 Brain (n = 109) vs not**

95.0 (50.1) vs 51.5 (5.9)

0.003

–

–

–

 Lung (n = 102) vs not

31.8 (6.0) vs 61.0 (7.4)

0.002

9.59

1.7 (1.21–4.04)

0.002

 Breast (n = 51) vs not

104.8 (20.3) vs 50.0 (5.6)

0.027

 MET (n = 31) vs not

30.6 (6.2) vs 58.4 (6.3)

0.013

–

–

–

 TP53 (n = 149) vs not

42.1 (6.1) vs 66.5 (10.3)

0.003

–

–

–

 PIK3CA (n = 42) vs not

43.2 (10.6) vs (58.4 (6.3)

0.013

–

–

–

 ARID1A (n = 19) vs not

24.8 (6.2) vs 58.4 (6.8)

0.002

7.98

2.7 (1.25–4.0)

0.005

 KRAS (n = 50) vs not

18.3 (7.3) vs 59.7 (6.5)

< 0.001

15.68

2.1 (1.5–3.12)

< 0.001

 ALK (n = 14) vs not

31.3 (9.0) vs 58.3 (6.7)

0.015

5.76

2.04 (1.14–3.7)

0.016

 SMAD4 (n = 12) vs not

21.7 (8.2) vs 58.3 (6.2)

0.007

–

–

–

 MYC (n = 20) vs not

22.2 (3.9) vs 59.1 (6.5)

< 0.001

7.59

2.17 (1.24–3.77)

0.006

Metastatic/recurrence at the time of blood draw vs not

53.6 (4.9) vs NR

0.011

–

–

–

 Liver (n = 111) vs not

49.3 (8.2) vs 59.1 (7.9)

0.023

4.85

1.4 (1.03–1.89)

0.028

 Lymph node (n = 139) vs not

39.9 (7.4) vs 74.1 (11.1)

< 0.001

–

–

–